Total revenues increased 20.3% to $1.2 billion, with System-wide sales up 16.1% to $1.4 billionIncome from operations margin of 2.3% and Restaurant level operating profit margin of 18.5% Net income of $19.4 million and Adjusted EBITDA of $120.9 million 64 system-wide restaurants opened across 23 states BRADENTON, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, t ...

HONG KONG, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Reitar Logtech Holdings Limited (NASDAQ: RITR) (“Reitar” or the “Company”), a market leader in Hong Kong’s smart logistics and automated warehousing sector, today announced that it has entered into a non-binding Memorandum of Understanding (the “MOU”) with Equator Capital Management SPC (“Equator Capital”), acting for and on behalf of the Segregated Portfolio “Equator Private Equity Fund SP,” a segregated portfolio company incorporated in the Cayman Islands (the ...

LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sompo, a leading global provider of commercial and consumer property and casualty (re)insurance, today announced the appointment of Sarah Stanford as Chief Executive Officer (CEO), Sompo UK following today’s completion of its Aspen acquisition. Ms Stanford, who was previously CEO, Aspen UK since March 2024, will now lead all of Sompo’s UK P&C Insurance operations. She will report to Alessa Quane, CEO, International Markets and continue to be based in London. Her app ...

Core Viewpoint - HPQ Silicon Inc. has successfully completed a non-brokered private placement, raising approximately $3 million CAD through the issuance of 18,181,819 units at a price of $0.165 CAD per unit, indicating strong institutional investor support [1][2]. Group 1: Offering Details - The private placement consists of units, each comprising one common share and one non-transferable common share purchase warrant, with warrants exercisable at $0.25 CAD for 24 months post-closing [3]. - The offering is expected to close around February 27, 2026, pending necessary approvals from the TSX Venture Exchange [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for general working capital, accelerating the execution of the Silicon-Based Battery Material pilot plant project, and continuing the development of hydrogen-based projects [4]. Group 3: Company Overview - HPQ Silicon Inc. is focused on advanced materials technology, particularly in the production of high-purity silicon and silica for energy storage and industrial applications [1][5]. - The company is collaborating with Novacium to develop next-generation silicon-based anode materials and is also working on clean-hydrogen and waste-to-energy technologies [5][6]. - HPQ aims to become a low-cost, zero-CO₂ producer of fumed silica and high-purity silicon, positioning itself to capture growth opportunities in energy storage and clean hydrogen markets [6].

Core Insights - The FDA has approved Dupixent (dupilumab) as the first and only treatment for allergic fungal rhinosinusitis (AFRS) in patients aged 6 years and older with a history of sino-nasal surgery, marking a significant advancement in the treatment of this condition [2][3][4] Group 1: Approval and Indications - Dupixent is now approved for treating nine distinct diseases driven by type 2 inflammation, including sino-nasal, skin, gut, and respiratory system diseases [6] - The approval was based on the LIBERTY-AFRS-AIMS phase 3 study, which demonstrated significant improvements in sinus opacification scores and nasal symptoms compared to placebo [4][10] Group 2: Clinical Study Results - In the LIBERTY-AFRS-AIMS study, Dupixent improved sinus opacification scores by 50% compared to 10% for placebo at Week 52, with a significant reduction also observed at Week 24 [4][11] - Patient-reported nasal congestion improved by 67% at Week 24 and 81% at Week 52 compared to 25% and 11% for placebo, respectively [7][13] - Dupixent reduced the risk of systemic corticosteroid use and/or surgery by 92%, with only 3% of patients on Dupixent requiring systemic corticosteroids compared to 31% on placebo [13] Group 3: Safety Profile - The safety profile of Dupixent in the LIBERTY-AFRS-AIMS study was consistent with its known safety profile in chronic rhinosinusitis with nasal polyps (CRSwNP), with common adverse reactions including injection site reactions and conjunctivitis [8][9] Group 4: Market Impact and Future Plans - Dupixent's approval is expected to establish a new standard of care for patients with AFRS, addressing a high unmet need in the treatment landscape [9] - Sanofi and Regeneron plan to submit additional applications to regulatory authorities worldwide to expand access to Dupixent [9][17]

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly reduced nasal signs and symptoms and systemic corticosteroid use or surgery compared to placeboAFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurr ...

Core Insights - Davis Commodities Limited has enhanced its position as a global agri-commodities platform, securing approximately US$20 million in orders and advanced discussions following a successful international food trade exhibition [1][12] - The company has generated around US$100 million in revenue from repeat customer transactions, indicating strong trade relationships and a growing preference for its services in key markets [2][3] Revenue Growth and Stability - The recurring demand from customers reflects trust in the company's execution capabilities and pricing discipline, which is crucial for earnings quality and financial stability [3] - The US$100 million in recurring revenue is increasingly driven by higher value-added products under the Maxwill brand, supporting a more resilient earnings profile over time [3][10] Strategic Partnerships - Davis Commodities has secured supply arrangements with leading FMCG manufacturers in Singapore, enhancing its customer portfolio and market credibility [5][6] - These partnerships are expected to contribute significantly to revenue continuity and strengthen the company's position as a preferred supply partner for high-volume procurement [6][7] Market Expansion and Financial Performance - The US$20 million pipeline from the exhibition demonstrates the company's ability to convert international market access into financial outcomes, primarily for essential food commodities [8][10] - The combination of new deals and repeat transactions creates a dual-engine growth model, positioning the company to benefit from resilient global demand [10][11] Management Strategy and Outlook - The management emphasizes disciplined execution, focusing on deepening partnerships, expanding into new markets, and growing the branded product portfolio [12][13] - The strong commercial outcomes and recurring revenue base provide a solid foundation for accelerated revenue recognition and improved earnings consistency [13][17] Operational Efficiency - The relationship-driven growth model reduces customer acquisition costs and improves working capital efficiency, enhancing operating cash flow generation [9][15] - The company aims to build a diversified, higher-margin earnings structure while maintaining transparent communication with capital markets [14][16]

U.S. Aluminum Company is new venture founded by Oklahoma City-based Plotkin Family, owners of leading aluminum fabrication company M-D Building ProductsINOLA, Okla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Local firm U.S. Aluminum Company has signed an agreement with EGA and Century Aluminum, the companies behind the planned primary aluminum production plant in Inola, Oklahoma, to explore the development of an aluminum fabrication plant near the new smelter. Click here to download photos of leaders from the three ...

INOLA, Okla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Local firm U.S. Aluminum Company has signed an agreement with EGA and Century Aluminum, the companies behind the planned primary aluminum production plant in Inola, Oklahoma, to explore the development of an aluminum fabrication plant near the new smelter. Click here to download photos of leaders from the three companies commemorating the agreement. The project, named Oklahoma Primary Aluminum, is expected to double U.S. primary aluminum production and make Ok ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the U.S. to treat nine distinct diseases driven in part by type 2 inflammation, i ...